Vitrolife AB (CHIX:VITRS) Cyclically Adjusted Revenue per Share: kr23.99 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:VITRS Vitrolife AB CHIX:VITRS
77 GF Score
Price kr105.75
GF Value kr185.92
! 6 Warning Signs
View Full Analysis

What is Vitrolife AB Cyclically Adjusted Revenue per Share?

Vitrolife AB CHIX:VITRS 77 Cyclically Adjusted Revenue per Share is kr23.99 as of Jun. 2026. GuruFocus rates CHIX:VITRS with a GF Score™ of 77/100 and a GF Value™ of kr185.92. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vitrolife AB's adjusted revenue per share for the three months ended in Jun. 2026 was kr6.328. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr23.99 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Vitrolife AB's average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vitrolife AB was 24.00% per year. The lowest was 13.90% per year. And the median was 18.40% per year.

As of today (2026-07-26), Vitrolife AB's current stock price is kr105.75. Vitrolife AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was kr23.99. Vitrolife AB's Cyclically Adjusted PS Ratio of today is 4.41.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vitrolife AB was 62.60. The lowest was 4.28. And the median was 22.55.


Vitrolife AB  (CHIX:VITRs) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vitrolife AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=105.75/23.99
=4.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vitrolife AB was 62.60. The lowest was 4.28. And the median was 22.55.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vitrolife AB Cyclically Adjusted Revenue per Share Related Terms


Vitrolife AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Vitrolife AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitrolife AB Cyclically Adjusted Revenue per Share Chart

Vitrolife AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.38 12.86 13.22 17.75 21.01

Vitrolife AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.75 19.87 21.01 19.57 23.99

CHIX:VITRS vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Vitrolife AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vitrolife AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vitrolife AB's Cyclically Adjusted PS Ratio falls into.


CHIX:VITRS
77GF Score
Vitrolife AB CHIX:VITRS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vitrolife AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vitrolife AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.328/134.1100*134.1100
=6.328

Current CPI (Jun. 2026) = 134.1100.

Vitrolife AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.939 101.138 2.571
201612 2.311 102.022 3.038
201703 2.249 102.022 2.956
201706 2.629 102.752 3.431
201709 2.265 103.279 2.941
201712 2.495 103.793 3.224
201803 2.432 103.962 3.137
201806 2.609 104.875 3.336
201809 2.616 105.679 3.320
201812 2.949 105.912 3.734
201903 2.874 105.886 3.640
201906 3.507 106.742 4.406
201909 3.482 107.214 4.356
201912 3.772 107.766 4.694
202003 3.076 106.563 3.871
202006 1.927 107.498 2.404
202009 2.949 107.635 3.674
202012 3.523 108.296 4.363
202103 3.491 108.360 4.321
202106 3.519 108.928 4.333
202109 3.461 110.338 4.207
202112 4.142 112.486 4.938
202203 5.554 114.825 6.487
202206 6.123 118.384 6.936
202209 5.894 122.296 6.463
202212 6.315 126.365 6.702
202303 6.307 127.042 6.658
202306 6.684 129.407 6.927
202309 6.263 130.224 6.450
202312 6.677 131.912 6.788
202403 6.211 132.205 6.300
202406 6.950 132.716 7.023
202409 6.395 132.304 6.482
202412 7.067 132.987 7.127
202503 6.218 132.825 6.278
202506 6.432 133.699 6.452
202509 6.166 133.480 6.195
202512 6.579 133.390 6.615
202603 5.959 133.560 5.984
202606 6.328 134.110 6.328

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr23.99 mean?
Vitrolife AB (CHIX:VITRS) has a Cyclically Adjusted Revenue per Share of kr23.99 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vitrolife AB and its competitors.
Is Vitrolife AB's Cyclically Adjusted Revenue per Share too high?
Vitrolife AB's current Cyclically Adjusted Revenue per Share is kr23.99. Overall, Vitrolife AB has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Vitrolife AB's Cyclically Adjusted Revenue per Share of kr23.99 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vitrolife AB and its competitors. Vitrolife AB's current Cyclically Adjusted Revenue per Share is kr23.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Vitrolife AB (CHIX:VITRS) has a current Cyclically Adjusted Revenue per Share of kr23.99. The stock's GF Value™ is kr185.92, compared to a current price of kr105.75 — trading 43.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr23.99. Vitrolife AB's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Cyclically Adjusted Revenue per Share is kr23.99 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?

Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued. The current stock price of kr105.75 is trading 43.1% below its estimated GF Value™ of kr185.92.

Key valuation signals for CHIX:VITRS:

  • Cyclically Adjusted Revenue per Share: kr23.99
  • GF Value™: kr185.92 vs. price of kr105.75 (43.1% below fair value)
  • GF Score™: 77/100 with 6 warning signs

No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vitrolife AB Business Description

Address Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
77GF Score

Get the complete analysis for CHIX:VITRS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr105.75
Price
kr185.92
GF Value